Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Part of paid clinical trials in Galloway, New Jersey.

Sponsor
Fox Chase Cancer Center
Study ID
NCT00553800
Phase
PHASE2
Status
Completed

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.

Key Dates

First listed
Nov 6, 2007
Start date
Jul 5, 2007
Status verified
Jun 2022
Primary completion
Jan 12, 2011
Completion
Jun 1, 2011

Study Design

Enrollment
32 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab & Erlotinib
    bevacizumab 15 mg/kg intravenous every three weeks and erlotinib pill 150 mg by mouth every day

Primary Outcome Measure

Progression Free Survival (PFS) [ Time Frame: 3 years ]

Locations (7)

FacilityCityStateZIPSite coordinators
AtlantiCare Regional Medical CenterGallowayNew Jersey08205-
Fox Chase Virtua Health Cancer Program at MemorialMount HollyNew Jersey08060-
Paoli HospitalPaoliPennsylvania19301-
Abramson Cnacer Center, University of PennsylvaniaPhiladelphiaPennsylvania19104-
Fox Chase Cancer CenterPhiladelphiaPennsylvania19111-
Pennsylvania Oncology Hematology AssociatesPhiladelphiaPennsylvania19106-
Grand View HospitalSellersvillePennsylvania18960-

Find similar trials in Galloway, NJ

By research site
AtlantiCare Regional Medical Center· Galloway, NJFox Chase Virtua Health Cancer Program at Memorial· Mount Holly, NJPaoli Hospital· Paoli, PAAbramson Cnacer Center, University of Pennsylvania· Philadelphia, PAFox Chase Cancer Center· Philadelphia, PAPennsylvania Oncology Hematology Associates· Philadelphia, PA

Related Studies